New hope for weight loss after GLP-1 failure: Stomach-Sewing procedure tested

NCT ID NCT07190794

Terminated Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This study looked at whether a procedure called endoscopic sleeve gastroplasty (ESG) could help people with obesity who stopped taking GLP-1 weight loss drugs because of side effects or poor results. Researchers compared weight loss and safety in 18 adults who either had ESG plus lifestyle changes or just lifestyle changes alone. The goal was to see if ESG offers a good alternative for those who cannot use GLP-1 medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Endoscopic sleeve gastroplasty (ESG) using the OverStitch or OverStitch NXT suturing system, plus lifestyle modification
What this could lead to: If successful, this could show that ESG is a safe and effective weight loss option for people who cannot tolerate or do not respond well to GLP-1 medications.
What could go wrong: This was a small, terminated study with only 18 participants, so results may not be reliable or apply to a broader population. ESG is a procedure with its own risks, such as infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Bariendo

Miami, Florida, 33179, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.